No Data
No Data
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
Navigating the Maze: Avenue Therapeutics Grapples With Regulatory Hurdles for IV Tramadol
Express News | CORRECTION: Avenue Therapeutics FY23 EPS $(0.98) Vs $(1.63) YoY
Express News | Avenue Therapeutics Q4 EPS $(0.98) Misses $(0.10) Estimate
Avenue Therapeutics 2023 Loss/Shr 98c >ATXI
Avenue Therapeutics 2023 Loss/Shr 98c >ATXI
Avenue Therapeutics: Nasdaq Granted Extension for Compliance to Continued Listing Through May 20 >ATXI
Avenue Therapeutics: Nasdaq Granted Extension for Compliance to Continued Listing Through May 20 >ATXI
No Data